Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern

Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelaye, Alehegn, Haidar, Abdallah, Kassab, Christina, Kazmi, Syed, Sinha, Prabhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819091/
https://www.ncbi.nlm.nih.gov/pubmed/27088018
http://dx.doi.org/10.1155/2016/1656182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819091/
https://www.ncbi.nlm.nih.gov/pubmed/27088018
http://dx.doi.org/10.1155/2016/1656182

Ejemplares similares